globenewswire

Receives Notice of Failure to File Interim Financial Statements in Violation of Nasdaq Listing Rules

WALTHAM, Mass. and STOCKHOLM, June 06, 2025 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals, Inc. (Nasdaq: APLS) and Sobi^® (STO:SOBI) today presented new data from the open-label period of the Phase 3 VALIANT study, investigating EMPAVELI^® (pegcetacoplan) for C3 glomerulopathy (C3G) and primary immune complex membranoproliferative glomerulonephritis (IC-MPGN). The data were presented as part of a late-breaking session at the European Renal Association (ERA) Congress.

This report provides comprehensive insights into market trends, drivers, and global tariff impacts. The growing demand for SMS firewalls is driven by increased messaging fraud, regulatory compliance needs, and the transition to 5G networks. Key regions include the U.S., China, and emerging markets in Asia-Pacific and Latin America. Discover detailed market analysis, competitive insights, and actionable strategies to leverage new revenue opportunities and navigate evolving threats in the SMS firewall landscape.

FORM 8.3

The partnership combines Blackpoint’s 24/7 MDR with UKON’s cyber insurance marketplace to equip MSPs with real-time protection, smarter coverage, and a new model for risk advising

Breakthrough Robotics and CRM Deployments Set Stage for Scalable Recurring Revenue Across Southeast Asia and Hong Kong

Company Executives Share Vision and Answer Questions Live at VirtualInvestorConferences.com

INDIANAPOLIS, June 06, 2025 (GLOBE NEWSWIRE) -- Hurco Companies, Inc. (Nasdaq: HURC) today reported results for the second fiscal quarter ended April 30, 2025. Hurco recorded a net loss of $4,063,000, or $0.62 per diluted share, for the second quarter of fiscal year 2025, which included a non-cash tax valuation allowance of $1,270,000 recorded in provision for income taxes. This net loss of $4,063,000 for the second quarter of fiscal 2025 compared to a net loss of $3,922,000, or $0.61 per diluted share, for the corresponding period in fiscal year 2024. For the first six months of fiscal year 2025, Hurco reported a net loss of $8,383,000, or $1.29 per diluted share, compared to a net loss of $5,570,000, or $0.86 per diluted share, for the corresponding period in fiscal year 2024. The net loss for the first six months of fiscal 2025 included $3,655,000 non-cash tax valuation allowance recorded in provision for income taxes.

MORRISTOWN, N.J., June 06, 2025 (GLOBE NEWSWIRE) -- via IBN -- Maybacks Global Entertainment, LLC, a wholly owned subsidiary of Authentic Holdings, Inc. (OTC:AHRO), has signed a Licensing and Distribution Agreement with Plex GmbH ("Plex").

Alvotech (NASDAQ: ALVO), a global biotech company specializing in the development and manufacture of biosimilar medicines for patients worldwide, announced today its participation in the Goldman Sachs 46th Global Healthcare Conference, which will be held in Miami, Florida June 9-11, 2025. Members of the management team will host one-on-one meetings at the conference. Dr. Balaji Prasad, Chief Strategy Officer, will participate in a fireside chat on Wednesday June 11, 2025, at 8:00 am EDT (12:00 GMT / 14:00 CEST).

HAMPTON, N.J., June 06, 2025 (GLOBE NEWSWIRE) -- Celldex Therapeutics, Inc. (NASDAQ:CLDX) today announced that Denice M. Torres has been elected to the company’s Board of Directors.